Last reviewed · How we verify
Stalevo
At a glance
| Generic name | Stalevo |
|---|---|
| Also known as | levodopa/carbidopa/entacapone, Entacapone, Levodopa and Carbidopa Tablets, Levodopa/Carbidopa/Entacapone |
| Sponsor | Orion Corporation, Orion Pharma |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease (PHASE4)
- Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease (PHASE4)
- A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 (PHASE3)
- Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) (PHASE2)
- A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa (PHASE3)
- Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease (PHASE4)
- Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States (PHASE4)
- Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stalevo CI brief — competitive landscape report
- Stalevo updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI